

Stakeholder Engagement and Materiality Assessment

Assessing Materiality: Evaluating Impact and Importance

In FY24, we reviewed key material topics in line with principles of 'double materiality' to align with evolving stakeholder priorities and our strategic objectives. This assessment considered both the impact of these topics on our business and the broader society,

allowing us to effectively identify and prioritise key Environmental, Social, and Governance (ESG) topics.

We engaged our Senior Management in reviewing the materiality assessment results and key material topics. To remain aligned with

changing external factors—such as competition, macroeconomic trends, consumer preferences, and regulatory demands—we have established a formal process that ensures continuous review and prioritisation of key material topics³².



³²GRI 3-1,3-2,3-3


- ☰
- I
- II
- III
- IV**
- V
- VI
- VII
- VIII

Our Materiality Topics for FY24

We have prioritised the importance of the relevant material topics for our business and visualised it as a materiality matrix.

The material topics in this matrix are an outcome of our stakeholder engagement and materiality assessment process. We reviewed each of these topics using the lens of double materiality. We have considered the perceived impact of the material topic on Sun Pharma’s business and ability to create, preserve, or erode value for stakeholders. We have also evaluated the impact of these topics on society and the environment through Sun Pharma’s business activities.

Materiality Matrix – FY24



- 1 Innovation Management
- 2 Climate Change
- 3 Environmental Impact Management
- 4 Corporate Governance and Business Ethics
- 5 Access to and Affordability of Medicines
- 6 Cyber Security and Data Privacy
- 7 Product Quality, Safety and Recall Management
- 8 Human Capital Development
- 9 Occupational Health and Safety
- 10 Diversity, Equity, and Inclusivity
- 11 Sustainable Supply Chain and Responsible Procurement
- 12 Social Impact through Community Engagement
- 13 Ethical Clinical Trials and Animal Testing

We prioritise monitoring our performance on key material topics. Our detailed Materiality Assessment and Management Approach is available in our FY24 Annual Report on page 88 at: <https://sunpharma.com/wp-content/uploads/2024/07/SPIL-Annual-Report-2023-24.pdf>